Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Annovis Bio, Inc.NYSE: ANVS
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital turns positive
Q1 FY2026 other working capital was $5.99M, compared with -$1.57M a year earlier. Trailing-twelve-month other working capital was $8.86M.
Context
- Other working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other working capital holds near $5.99M or moves back toward the trailing-twelve-month quarterly average of $2.21M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 1.29M USD
- Year-over-year change
- +490.5%
- 4-year CAGR
- +42.8%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.29M | +490.5% |
| FY2024 | 2024-12-31 | (331.43K) | -113.6% |
| FY2023 | 2023-12-31 | 2.44M | +155.3% |
| FY2022 | 2022-12-31 | (4.41M) | -1517.4% |
| FY2021 | 2021-12-31 | 311.13K | — |
Other Working Capital vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's LTM Mar 2026 other working capital of $8.86M is the 3rd largest of the 6 companies compared; the peer median is $167.48K.
- Its year-over-year change of +1521.5% is the 2nd highest of 5, against a peer median of +148.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $37.03M | +5891.4% | — | 105.5% | |
| LTM Dec 2025 | $12.67M | +22.6% | +36.1% | 47.7% | |
| LTM Mar 2026 | $8.86M | +1521.5% | — | — | |
| LTM Mar 2026 | $2.47M | +167.7% | — | — | |
| LTM Mar 2026 | $167.48K | +130.1% | +29.8% | — | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding ANVS) | $167.48K | +148.9% | +33.0% | 76.6% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59B) | (28.85B) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.7M | 9.15M | 4.63M | 3.84B | 1.8B |
| Change in Working Capital | 657.35K | (1.14M) | (228.6K) | 681.71K | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 346.22K | 3.27M | (2.67M) | 1.01M | 284.54K |
| Other Working Capital | 311.13K | (4.41M) | 2.44M | (331.43K) | 1.29M |
| Other Non-Cash Items | 0 | 0 | 11.84M | (1.14B) | 1.44B |
| Operating Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 46.65M | 4.61K | 16.89M | 18.67M | 34.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 95.1K | 0 | 458.39K | 26.67B | 34.57B |
| Financing Cash Flow | 46.74M | 4.61K | 17.34M | 26.69B | 34.6B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.61M | (17.31M) | (22.62M) | 4.8B | 8.98B |
| Free Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.